Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 5, 2011, Pages 555-562

  Yokote, Koutaro ^a   Shimano, Hitoshi ^b   Urashima, Mitsuyoshi ^c   Teramoto, Tamio ^d  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CKD; efficacy; eGFR; HbA1c; HDL C; LDL C; pitavastatin; safety

Indexed keywords

CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN INFARCTION; CATARACT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE WEAKNESS; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; OBSTRUCTIVE JAUNDICE; RHABDOMYOLYSIS; SIDE EFFECT; SYNCOPE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNCONSCIOUSNESS;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; QUINOLINES; RENAL INSUFFICIENCY;

EID: 79959232592     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.47     Document Type: Article

References (34)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian simvastatin survival study (4S)Lancet 344, 1383-1389 (1994)
2. Shepherd J, Cobbe SM, Ford I et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307 (1995)
3. Nakamura H, Arakawa K, Itakura H et al.Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study), a prospective randomized controlled trial. Lancet 368, 1155-1163 (2006) (Pubitemid 44444932)
4. Teramoto T, Shimano H, Yokote K et al.New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11(5), 817-828 (2010)
5. Hayashi T, Yokote K, Saito Y. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin. Pharmacother. 8, 2315-2327 (2007). (Pubitemid 350001592)
6. Saito Y, Yamada N, Teramoto T et al.A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162(2), 373-379 (2002) (Pubitemid 34457943)
7. Teramoto T, Saito Y, Yamada N et al.Clinical safety and efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia. Results of a multicenter long-term study. J. Clin. Ther. Med. 17(6), 885-914 (2001)
8. Sone H, Takahashi A, Shimano H et al.HMG-CoA reductase inhibitor decreases small dense LDL and remnant-like particle cholesterol in patients with Type-2 diabetes. Life Sci. 71(20), 2403-2412 (2002) (Pubitemid 35264612)
9. Noji Y, Higashikata T, Inazu A et al.Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163(1), 157-164 (2002) (Pubitemid 34615738)
10. Ouchi Y, Saito Y, Ito H et al.Efficacy and safety of NK-104 (pitavastatin), a new HMG-CoA reductase inhibitor in the elderly patients with hyperlipidemia. Geriatr. Med. 39, 849-860 (2001)
11. Kurihara Y, Douzono T, Kawakita K et al.A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet) - Livalo effectiveness and safety (LIVES) Study. Jpn Pharmacol. Ther. 36, 709-731 (2008)
12. Teramoto T, Shimano H, Yokote K et al.Effects of pitavastatin (Livalo tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia - sub-analysis of Livalo Effectiveness and Safety (LIVES) study. J. Atheroscler. Thromb. 16, 654-661 (2009)
13. Kimura K, Shimano H, Yokote K et al.Effects of pitavastatin (Livalo tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease-sub-analysis of the Livalo Effectiveness and Safety (LIVES) study. J. Atheroscler. Thromb. 17(6), 601-609 (2010)
14. Teramoto T, Sasaki J, Ueshima H et al.Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler. Thromb. 14(2), 45-50 (2007)
15. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of low density cholesterol in plasma without the use of a centrifuge. Clin. Chem. 18, 449-502 (1972)
16. Bianchi S, Bigazzi R, Caiazza A et al.A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 41, 565-570 (2003) (Pubitemid 36278373)
17. Sandhu S, Wiebe N, Fried LF et al.Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol. 17, 2006-2016 (2006) (Pubitemid 44036185)
18. Collins R, Armitage J, Parish S et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003)
19. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol. 14, 1605-1613 (2003) (Pubitemid 36687063)
20. Athyros VG, Mikhailidis DP, Papageorgiou AA et al.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J. Clin. Pathol. 57, 728-734 (2004)
21. Shepherd J, Kastelein JJ, Bittner V et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J. Am. Coll. Cardiol. 51, 1448-1454 (2008) (Pubitemid 351471787)
22. Matsuo S, Imai E, Horio M et al.Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982-992 (2009)
23. Sasaki J, Ikeda Y, Kuribayashi T et al.A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on HDL-cholesterol levels and glucose metabolism in Japanese patients with elevated levels of LDL-cholesterol and glucose intolerance. Clin. Ther. 30(6), 1089-1101 (2008) (Pubitemid 351978115)
24. Maejima T, Yamazaki H, Aoki T et al.Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 324, 835-839 (2004) (Pubitemid 39345591)
25. Levey AS, Coresh J, Balk E et al.National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139, 137-147 (2003)
26. Go AS, Chertow GM, Fan D et al.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004)
27. Matsushita K, van der Velde M, Astor BC et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073-2081 (2010)
28. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 16, 2152-2157 (2001) (Pubitemid 33062136)
29. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28, 2728-2732 (2005) (Pubitemid 43951167)
30. Ansell BJ, Watson KE, Fogelman AM et al.HDL function: recent advances. J. Am. Coll. Cardiol. 46, 1792-1798 (2005)
31. Sasaki J, Iwashita M, Kono S et al.Statins: beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb. 13, 123-129 (2006)
32. Rajpathak SN, Kumbhani DJ, Crandall J et al.Statin therapy and risk of developing Type 2 diabetes: a meta-analysis. Diabetes Care 32, 1924-1929 (2009)
33. Sattar N, Preiss D, Murray HM et al.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010)
34. Hiro T, Kimura T, Morimoto T et al.Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study)J. Am. Coll. Cardiol. 54(4), 293-302 (2009).